We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
7 own
3 watching
Current Price
$19.93
$-0.23
(-1.14%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
709.02M
52-Week High
52.43
52-Week Low
16.21
Average Volume
0.07M
Dividend Yield
--
P/E Ratio
--
Market Capitalization709.02M
52-Week High52.43
52-Week Low16.21
Average Volume0.07M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
We are a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. We leverage our deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies. --- We were incorporated in October 2019 under the laws of the State of Delaware. Our principal executive offices are located at 139 Main Street, Cambridge, MA 02142, and our telephone number is (339) 217-0162. We have one subsidiary located in Belgium, iTeos Belgium SA, which was incorporated in August 2011 under the laws of Belgium. Our website address is www.iteostherapeutics.com.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Ticker Report
5 months ago
iTeos Therapeutics, Inc. (NASDAQ:ITOS Get Rating) Director David Hallal sold 1,171 shares of the companys stock in a transaction on Thursday, June 9th. The shares were sold at an average price of $19.51, for a total value of $22,846.21. The sale was disclosed in a legal filing with ...
Zolmax
6 months ago
Lazard Asset Management LLC purchased a new position in iTeos Therapeutics, Inc. (NASDAQ:ITOS Get Rating) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 3,837 shares of the companys stock, valued at approximately $178,000. ...
Globe Newswire
7 months ago
Innoskel Appoints Dr Michel Detheux as Chairman Nice, France, 12 April 2022 Innoskel (the Company), a pioneering biotechnology company developing transformative therapies for the unmet needs of individuals with rare bone disorders, today announced the appointment of Dr Michel Detheux as Chairman of ...
Globe Newswire
7 months ago
Treatment with EOS-448 results in a decrease of TIGIT-positive cells in tumor biopsies, the first evidence of a treatment effect in the tumors of patients treated with an anti-TIGIT antibodyIn preclinical studies and in blood samples from patients with advanced cancers, treatment with EOS-448 ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$19.93
$-0.23
(-1.14%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00